Last reviewed · How we verify
Tinzaparin,Therapeutic anticoagulation
At a glance
| Generic name | Tinzaparin,Therapeutic anticoagulation |
|---|---|
| Also known as | TA |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Caprini Score in Venous Surgery: a Prospective Cohort Study
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis (PHASE4)
- Anticoagulation-free VV ECMO for Acute Respiratory Failure (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: